A UK population simulation study indicates that screening all newly diagnosed females with breast cancer for mutations in BRCA1/2 & PALB2 is cost-effective and would prevent 2,101 cases of breast/ovarian cancer & 633 cancer deaths per year.

This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2752373